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ABBREVIATIONS AND ACRONYMS 
 
AIDS      Acquired Immunodeficiency Syndrome 
AJCC      American Joint Committee on Cancer 
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PR              Partial Response 
RECIST    Response Evaluation Criteria In Solid Tumours 
RMT          Retromolar Trigone 
RT               Radiotherapy 
SCC             Squamous cell carcinoma 
STD             Sexually Transmitted Diseases 
TNM            Primary Tumor, Regional Nodal Metastases, Distant Metastasis 
TvMCH      Tirunelveli Medical College 
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GLOSSARY 
Quid                             Betal nut is chewed in combination with lime and cured tobacco as a 
mixture 
Retromolar Trigone   Retromolar trigone is represented by tissue posterior to the posterior 
inferior alveolar ridge and ascends over the inner surface of the ramus of the mandible 
Sideropenic dysphagia  Plummer Vinson syndrome. It’s a triad of Dysphagia [Esophageal 
webs], Iron Deficiency Anemia and Glossitis.   
18 
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INTRODUCTION 
        Squamous cell carcinoma is an aggressive neoplasm ranking sixth worldwide. Oral 
cavity malignancy is of squamous in origin and it accounts for 95% of head and neck 
malignancies.
1
Most cases of oral malignancies are diagnosed at an advanced stage in the 
Indian subcontinent. Incidence of oral malignancies is more common in the Indian setup 
when compared to the western world. In developed countries, the incidence among the 
annually diagnosed neoplasms is 3% compared to Asia and India (developing countries) 
where it represents almost 30%.
2
Various clinical and histopathological factors have been 
addressed in oral malignancies. 
    The American Joint Committee on Cancer (AJCC) staging system classified head and neck 
malignancies into six major groups: lip and oral cavity, pharynx, larynx, nasal cavity and 
paranasal sinuses, major salivary glands, and thyroid. Male preponderance in aerodigestive 
tract malignancies has been noted significantly, but male-to-female ratio is steadily 
decreasing because of the increased incidence of female smokers. The highest incidence areas 
of France, Hong Kong, India, Spain, Italy, and Brazil, as well as in U.S. blacks incidence in 
males exceed 30 per 100,000. The highest female rate greater than 10 per 100,000 is found in 
association with chewing of betel quid and tobacco in India.
3
 In India, cancer is the second 
most common disease responsible for maximum mortality with about 0.3 million deaths per 
year.
4
 Mouth and oropharynx is the most common malignancy in males and third most 
common malignancy in females following cervix and breast as per ICMR 2004.
5
 
 
In oral mucosa, a continuous spectrum is observed beginning with preinvasive lesions, ending 
with invasive carcinomas and metastasis.
1
 Tobacco abuse and alcoholism are the two most 
common risk factors which are modifiable in the development of head and neck malignancies 
and oral malignancies in particular.
6
 The other risk factors associated are environmental UV 
20 
 
light, poor nutrition, HPV infection, immunosuppression, mechanical irritation, thermal 
injury, and chemical exposure, chronic infection with syphilis and  Plummer-Vinson 
syndrome.
6,7 
Mechanical irritation, thermal injury and chemical exposure have been 
addressed after noting their association with pipe smoking. The risk factors are synergistic 
and not only additive, especially tobacco use and alcoholism
6
. Chronic exposure to risk 
factors lead to precursor/preinvasive lesions by two hit process- DNA damage and the ability 
of mutated cells to progress through the rest of the cell cycle, leading  to invasive lesions.
6
 
  Various clinical and histopathological factors have been addressed in oral malignancies to 
help in prognosticating the disease process to aid in formulating treatment protocol. Hence 
this study has been undertaken to evaluate the factors in prognosticating oral malignancies. 
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REVIEW OF LITERATURE 
Majority of the neoplasms of the head and neck is represented by Squamous cell carcinoma 
accounting to about 95%.
1
Hence the diagnosis and treatment of lesions in the head and neck 
including oral cavity require a systematic approach.
6
 The American Joint Committee on 
Cancer (AJCC) staging system classified head and neck malignancies into six major groups: 
lip and oral cavity, pharynx, larynx, nasal cavity and paranasal sinuses, major salivary glands, 
and thyroid.
5 
History  
 The first clinical description of oral cancer was by Sushruta almost 2500 years back in his 
“Sushruta Samhita”.7 In 1902, Niblock8 has reported high incidence of oral cancer, 
particularly cancer buccal mucosa in southern parts of India and indicated that this was due to 
the frequent habit of chewing pan and tobacco and the disease site most often found at the 
site of long standing contact of quid to mucosa. Balram
8
, in the same year, expressed the 
view that slaked lime as the main source of carcinogen in buccal mucosal cancer.
 
 
Fells
8
 reported a series of 390 cases of malignant diseases, reported 346 oral cancers, with 
buccal mucosal cancer constituting 83% of it. Abba
8
 incriminated that the etiological agent of 
oral cancer to be tobacco in the year 1915. The development of premalignant lesions which 
later develop into cancer with prolonged and continuous use of tobacco was suggested by 
Bloodgood
8
 in 1921. Orr
9
 in the year 1933, attributed shell lime use and nutritional 
deficiencies as the cause of cancer, after observing the fact that oral cancer was less in 
incidence in northern India when compared to the south. The high incidence of palatal cancer 
in people with habit of smoking of chutta with burning end inside the mouth [reverse 
smoking] was reported by Kini and Rao in 1937.
8
 Ackermann, in the year 1948 suggested 
verrucous carcinoma was a distinct entity of squamous carcinoma.
10,11
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The first WHO accepted classification for oral and oropharyngeal tumours was given in the 
year 1971 by Wahi P.N., Cohen B, Luthra V.K., and Torloni H.
12
 The recent WHO 
classification of tumours of oral cavity was given in the year 2003 and it broadly classifies 
into the following types 
Malignant epithelial tumors 
Epithelial precursor lesions 
Benign epithelial tumors 
Salivary gland tumors   
Soft tissue tumors 
Hematolymphoid tumors 
Mucosal malignant lymphoma 
Secondary tumors
13
 
Anatomy 
The extension of oral cavity is from the vermilion border of the lip to the hard-palate/soft- 
palate junction superiorly, to circumvallate papillae inferiorly, and to the anterior tonsillar 
pillars laterally. It is further subdivided into seven sites: lips, alveolar ridges, oral tongue, 
retromolar trigone, floor of mouth, buccal mucosa, and hard palate.
6
 With these subsites 
specific anatomic relationships affect diagnosis, spread, and its treatment. The contiguous 
spread of tumors is determined by the course of the nerves, blood vessels, lymphatic 
pathways, and by the fascial planes. The fascial planes serve as barriers to the direct tumor 
invasion and pattern of regional lymph nodal spread.
6
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Figure 1 Anatomy of Oral Cavity 
 
Epidemiology  
Male preponderance in aerodigestive tract malignancies has been noted significantly, but 
male-to-female ratio is steadily decreasing because of the increased incidence of female 
smokers. The highest incidence areas of France, Hong Kong, India, Spain, Italy, and Brazil, 
as well as in U.S. blacks incidence in males exceed 30 per 100,000. The highest female rate 
greater than 10 per 100,000 is found in association with chewing of betel quid and tobacco in 
India.
3
 In developed countries, the incidence among the annually diagnosed neoplasms is 3% 
compared to Asia and India (developing countries) where it represents almost 30%.
2
 In India, 
cancer is the second most common disease responsible for maximum mortality with about 0.3 
million deaths per year.
4
 Mouth and oropharynx is the most common malignancy in males 
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and third most common malignancy in females following cervix and breast as per ICMR 
2004.
5
 
Etiology    
In oral mucosa, a continuous spectrum is observed beginning with preinvasive lesions, ending 
with invasive carcinomas and metastasis.
1
 Tobacco abuse and alcoholism are the two most 
common risk factors which are modifiable in the development of head and neck malignancies 
and oral malignancies in particular.
6
 The other risk factors associated are environmental UV 
light, poor nutrition, HPV infection, immunosuppression, chronic infection with syphilis and  
Plummer-Vinson syndrome.
6,14
 Factors such as mechanical irritation, thermal injury, and 
chemical exposure have been described especially for cancer lip based on the practice of pipe 
smoking
6
. The risk factors are synergistic and not only additive, especially tobacco use and 
alcoholism.
6,15
 Chronic exposure to risk factors lead to precursor/preinvasive lesions by two 
hit process- DNA damage and the ability of mutated cells to progress through the rest of the 
cell cycle, leading  to invasive lesions.
6
   
Carcinogenesis 
Loss of cellular signaling mechanisms leads to the development of tumour. Following 
malignant transformation, mitosis, apoptosis and the various cellular processes of and the 
interaction of a cell with its surrounding environment are altered. Overexpression of mutant 
p53 is a key event in the malignant transformation of more than 50% of head and neck 
squamous cell carcinomas in smokers. 
Genetic mutations may occur either de novo or due to environmental exposure to radiation or 
viral pathogens. Loss of heterozygosity at 3p, 4q, and 11q13 and various common mutations 
26 
 
in head and neck malignancies are seen more frequently in smokers.
3,6
 Multiple head and 
neck primaries can be explained by field cancerization theory by Slaughter and associates.
6 
 
TNM staging of Oral cavity Carcinoma
6
 
 
Primary tumor 
TX Unable to assess primary tumor 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor is <2 cm in greatest dimension 
T2 Tumor >2 cm and <4 cm in greatest dimension 
T3 Tumor >4 cm in greatest dimension 
T4 (lip) Primary tumor invading cortical bone, inferior alveolar nerve, floor of mouth, or 
skin of face (e.g., nose or chin) 
T4a 
(oral) 
Tumor invades adjacent structures (e.g., cortical bone, into deep tongue 
musculature, maxillary sinus) or skin of face 
T4b 
(oral) 
Tumor invades masticator space, pterygoid plates, or skull base and/or encases the 
internal carotid artery 
Regional lymphadenopathy 
Nx Unable to assess regional lymph nodes 
N0 No evidence of regional metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
27 
 
N2a Metastasis in single ipsilateral lymph node, >3 cm and <6 cm 
N2b Metastasis in multiple ipsilateral lymph nodes, all nodes <6 cm 
N2c Metastasis in bilateral or contralateral lymph nodes, all nodes <6 cm 
N3 Metastasis in a lymph node >6 cm in greatest dimension 
Distant metastases 
Mx Unable to assess for distant metastases 
M0 No distant metastases 
M1 Distant metastases 
 
Group staging
6 
Stage 0                 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
T1-3 N1 M0 
Stage Iva T4a N0 M0 
T4a N1 M0 
T1-4a N2 M0 
Stage IVb Any T N3 M0 
T4b Any N M0 
Stage IVc Any T Any N M1 
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Clinical staging is based primarily on palpation, but radiographic studies, including computed 
tomography (CT) and magnetic resonance imaging (MRI), have been shown to be accurate in 
staging the cancer as the detection of nodes clinically impalpable is amenable for study using 
imaging modalities.
3
 
The sub classification of stage IV is as follows 
Stage IVA              Advanced resectable 
Stage IVB              Advanced unresectable 
Stage IVC              Advanced distant metastatic disease
3 
Grading of the primary tumour is as follows 
Gx   Grade cannot be assessed 
G1   Well differentiated tumour 
G2   Moderately differentiated tumour 
G3  Poorly differentiated tumour
16
   
The cervical lymphatic nodes are divided into seven levels.  
 
1 Level I – Submental and submandibular group  
 
•  Level IA - bounded by the anterior belly of the digastric muscle, the hyoid bone, 
and the midline (submental triangle).  
 
•  Level IB - bounded by the anterior and posterior bellies of the digastric muscle and 
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the inferior border of the mandible. Level IB contains the submandibular gland 
along with the lymph node.  
 
 
2.  Level II – Upper Deep cervical group 
Bounded superiorly by the skull base, anteriorly by the stylohyoid muscle, inferiorly by a 
horizontal plane extending posteriorly from the hyoid bone(upto hyoid bone inferiorly), 
and posteriorly by the posterior edge of the sternocleidomastoid muscle [between base of 
skull to hyoid bone].  
   
   
 
 
3.  Level III – Middle Deep cervical group 
Begins at the inferior border of hyoid to the horizontal plane extending posteriorly from 
the inferior border of the cricoid cartilage. and is bounded by the laryngeal strap muscles 
anteriorly and by the posterior border of the sternocleidomastoid muscle posteriorly. 
 
4.  Level IV- Lower Deep cervical group 
Begins at the inferior border of cricoid cartilage to the clavicle bounded anteriorly by the 
strap muscles and posteriorly by the posterior edge of the sternocleidomastoid muscle. 
 
5.  
 
 
6.  
Level V – Posterior group 
It is posterior to the posterior edge of the sternocleidomastoid muscle, anterior to the 
trapezius muscle, superior to the clavicle, and inferior to the base of skull. 
Level VI – Pretracheal, paratracheal and prelaryngeal group 
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 Figure 2 Levels of lymph nodes 
Bounded by the hyoid bone superiorly, the common carotid arteries laterally, and the 
sternum inferiorly. 
 
 7. 7. Level VII – Superior mediastinum 
Lies between the common carotid arteries and is superior to the aortic arch and inferior to 
the upper border of the sternum.
3
  
Figure 3 Levels of lymph nodes 
31 
 
Evaluation 
Careful evaluation and accurate staging, both clinically and radiographically is required 
for proper treatment of oral malignancies. 
Symptoms   
Ulcer 
Bleeding 
Loose teeth 
Difficulty or pain when swallowing 
Difficulty wearing dentures 
Lump in the neck 
Earache 
Pre-existing lesions – Leukoplakia, Erythroplakia, lichen planus, oral submucous fibrosis, 
syphilitic glossitis and sideropenic dysphagia
17
 
 
Investigations 
3
 
1. Biopsy from the suspected site of malignancy 
2. FNAC from cervical lymph nodes 
3. Contrast CT scan of head and neck – to accurate stage the disease especially in 
evaluating bony destruction 
4. MRI can determine soft tissue involvement excellently 
5. Chest radiography or chest CT is performed to rule out synchronous lung lesions 
32 
 
6. Tumour markers-  Alkaline phosphatase and S Calcium- not routinely done 
7. Positron Emission Tomography CT – role of PET CT in head and neck cancers has 
not been proven comprehensively and is under investigation. The basis of PET 
scan is that the glucose analogue Fluorodeoxyglucose F 18 is preferentially 
absorbed by neoplastic cells and is evident by positron emission tomography 
(PET). PET has more sensitivity in identifying primary in head and neck but its 
sensitivity in not more than 50% in detecting unknown primary tumours.
3
  
 
Anatomic sites 
Lip 
Anatomically, lip is a transition from external skin to internal mucous membrane 
occurring at vermilion border. Risk factors in the development of carcinoma lip are 
prolonged exposure to sunlight, fair complexion, immunosuppression, and tobacco use. 
Diagnosis of lip cancer is early as it is amenable for inspection and it bleeds on contact. 
Figure 4 Lip cancer 
Early lesions, T1 and T2 are usually treated by wide local excision in the form of wedge 
resection of the lip with primary closure. Primary radiation therapy is also highly effective 
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in these lesions and comparable to surgery. Larger lesions require combination therapy in 
the form of surgery- resection of involved tissues with neck dissections with complex 
reconstruction, and adjuvant radiation therapy. The size of the lesion, size of mouth and 
the presence of dentition determine primary closure in lip cancers after resection of 
primary.
18
  
Buccal mucosa 
Mucosa covering the cheeks and lips is called buccal mucosa. In practice, mucosa 
covering cheek is called buccal mucosa. It is in continuity with the gingiva of the 
maxillary and mandibular alveolar ridge along the buccal aspect and also retromolar 
trigone. Buccal SCC are commonly low grade tumours spreading submucosally along the 
buccinator muscle.
19 
Verrucous carcinoma, a variant of SCC is seen in the buccal mucosa 
frequently than other regions and is indolent when compared to SCC.
15
 Evaluation of a 
Figure 5 Cancer Cheek with oro cutaneous fistula 
buccal or gingival mucosal lesion should be done meticulously so as to address the extent 
of submucosal spread, osseous involvement, involvement of adjacent structures like 
retromolar trigone, pterygomandibular raphe, and cervical lymphatic spread which is 
34 
 
Figure 6 Cancer Cheek 
better delineated using CT scan and MRI.
20 
Retromolar trigone 
Retromolar trigone is represented by tissue posterior to the posterior inferior alveolar ridge 
and ascends over the inner surface of the ramus of the mandible. It is one of the areas of 
surgical graveyards in head and neck as the malignancy is not amenable for clinical 
examination easily and hence imaging evaluation of the retromolar trigone is critical. 
Posterior spread of cancer RMT to involve mandible is seen early.
19
 It may also be 
involved by regional extension. CT scan seldom gives complete information because of 
artefacts and MRI is essential in evaluating retromolar trigone.
20
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Gingiva 
Gingival/alveolar cancer tends to involve the bone in around 50% patients. The diagnosis 
is delayed in this region as the symptoms are neglected common dental conditions like 
gingivitis and periodontitis.  The propensity to metastasise to lymph nodes is high but 
mostly confined to levels I and II. Early lesions are confined to the mucoperiosteum and 
resection may require a marginal mandibulectomy to remove the lesion in toto. Larger 
lesions involving adjacent structures like skin, floor of mouth and large areas of buccal 
 mucosa [T4a- resectable] need extensive resection with reconstruction in the form of 
Figure 7 Cancer Gingiva 
pectoralis major myocutaneous flap, deltopectoral flap, tongue flap, forehead flap etc.
21
 
Floor of mouth  
Carcinoma of floor of mouth arises within 2 cm of the anterior midline
19
 and present as 
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painful infiltrative ulcers partly due to the involvement of the muscles of the floor of 
 Figure 8 Cancer Floor of Mouth 
mouth, and partly due to adjacent structure involvement-middle of the mandible or tongue. 
Submandibular and submental lymph nodes are positive for metastatic disease due to 
malignancy in this region. Early disease can be treated by either surgery or RT as the 
lesions respond to both modalities equally. Advanced lesions need surgical resection with 
reconstruction and adjuvant RT.
21
 
Oral Tongue 
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Incidence of cancer tongue is increasing in the present world with more and more cases 
diagnosed in young people. In cancer tongue, the lateral border is the most common 
location, followed by the anterior tongue and the dorsum.
15,19
 Lymph nodal metastasis is 
rare in early lesions with levels II, III, I getting involved in late lesions in decreasing order. 
Commonest cancer in oral cavity after lip cancer and carcinoma buccal mucosa. For early 
disease, surgery and RT have been proven equally effective. Tumours of the Anterior third 
tongue invade the ﬂoor of the mouth and middle-third lesions invade the tongue 
musculature.
19
 Excision usually entails a hemiglossectomy to obtain negative margins as 
tumour cells extend well beyond the clinically detected margin.  In infiltrative type of 
cancer tongue either adjuvant RT to the neck or elective neck dissection should be 
considered.
21
 
Hard palate 
Figure  10 Cancer Hard Palate 
Primary Hard palate malignancy is seen predominantly in males and is rare. Squamous cell 
38 
 
carcinoma comprises only 50% of the neoplasms in hard palate as minor salivary glands 
are seen in highest number
13
. Adenocarcinoma and adenoid cystic carcinoma is seen 
almost on par with squamous cell carcinoma in this region amounting to the rest. Lymph 
node metastasis is uncommon in hard palate (6-29%) and the presence of lymph node 
metastasis denotes aggressive nature of disease. Surgical treatment entails extensive 
resection in the form of infrastructure maxillectomy or near total palatectomy with 
immediate prosthetic obturator.
21
 
Treatment 
         Treatment of oral cancer includes surgery, radiation therapy, or chemotherapy or 
combination therapy in the form of multimodal therapy. 
Surgical-            Wide local exicision with or without radical neck dissection 
Radiotherapy-    Curative  - 50-70 Gy in 200 # for 30 cycles 
                           Palliative tailored according to the patient[ 40-45Gy] 
Chemotherapy- Cisplatin based chemotherapy [50- 70mg/m
2
 every 3 weeks]
22
 
Surgery: It involves wide local excision along with a rim of normal tissue with or without 
lymph node dissection. Surgical procedure is based on the site of lesion, extent of lesion 
and presence and absence of lymphnodal involvement. Complex surgical resections are 
39 
 
done in various clinical settings with flap cover to cover the resultant defect.
3,6
 Time 
 required for recovery of the patient who has undergone a complex surgical procedure is 
more than one who has undergone only wide local excision.
23
 Also the morbidity caused  
                    Figure 12. Cancer lip/cheek        Figure 13. Wide excision for ca lip/cheek 
by complex procedures in the form of flaps and reconstructive surgeries to be considered. 
                                                                           Figure 14.  Forehead Flap  
Radiotherapy: Radiation therapy uses high-energy rays to destroy cancer cells.  Two types of 
radiation therapy to treat oral cancer: 
External radiation: The radiation comes from a machine harbouring radioactive 
40 
 
device.  
Internal radiation (implant radiation): Radiation comes from radioactive material 
placed in seeds, needles, or thin plastic tubes placed directly in the tissue. The implants 
remain in place for several days. 
Both internal and external devices may be used for the same patient.
23
 
Radiation doses are chosen as to maximize tumor control with acceptable side effects. 
Complete response is when the size of tumor reduces from 3 cm diameter to 3 mm, which 
still leaves 100 million tumor cells as normally a tumor of size one cm cube contains one 
billion cells. Each radiation fraction kills a certain amount of tumor fraction, the radiation 
dose required to cure occult cancer is more. With standard fractionation, 45 – 54 Gy is 
used when there is moderate suspicion of occult disease as adjuvant radiotherapy, 60 – 65 
Gy for high suspicion of occult disease or for positive margins and for grossly left over 
tumor, the dose is more than 70 Gy.
22
  
The standard fractionation of RT is defined as the delivery of one treatment of 1.8 to 2.25 
Gy per day. This is based on the understanding of chance of tumor control and risk of 
normal tissue damage. Accelerated fractionation is a technique in RT which has developed 
from head and neck malignancies due to the fact that protracted treatment due to 
increasing radiation dose was associated with loss of tumour control due to accelerated 
repopulation. Accelerated fractionation completes RT before tumour cells enter the 
accelerated repopulation phase, in which after administering the standard radiation dose in 
the morning, concomitant boost [second treatment to boost field in the afternoon] is given. 
Hyperfractionation uses the same principle of accelerated fractionation, but the dose per 
fraction is less than the standard fraction with more fractions delivered to the patient. This 
is expected to cause less late complications for the same acute effects on tissues, both 
41 
 
normal and tumour.
22
   
Hypofractionation is the technique of administration of smaller number of fractions of 
higher dosages, used in the setting of palliative RT and is known to cause more late 
toxicity. 
22
  
Shrinking field technique is a technique used in the setting of gross disease, where 50 Gy 
dose is delivered to the entire region and additional boost dose of 20 Gy to the tumor. The 
principle behind this is that gross tumor invariably resides within the region at risk for 
radiotherapy. With the development of intensity modulated RT [IMRT], both the regions 
are treated simultaneously achieving the goals. 
22
 
RT alone is used as curative modality in the setting of localized tumors. The decision to go 
for RT or surgery is determined by tumor characteristics. If the risk of recurrence after 
surgery is low, or if the recurrence is easily controlled by second resection, surgery is 
preferred. Whereas if the morbidity is more with tumor resection, gross tumour resection 
is still associated with high risk of residual disease, RT is preferred. Adjuvant RT can 
reduce local failure rates to below 10% if gross tumor resection is achieved. 
22
  
In neoadjuvant setting, RT is preferred in head and neck cancers as this setting can be 
readily administered than adjuvant therapy with less morbidity than with adjuvant setting 
and efficacy almost equal to adjuvant RT.  
Indications for RT in adjuvant setting
22
 are 
Close [5 mm] or positive margin 
Extracapsular extension 
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Multiple positive nodes 
Invasion of soft tissues of neck 
Endothelial-lined space invasion 
Perineural invasion 
Long term survival benefit from RT in malignancies is achieved by the use of effective 
chemotherapy along with RT by preventing deaths due to early metastatic disease 
especially if CT is moderately effective. Adjuvant radiation has little influence on survival 
benefit if CT is ineffective or very effective, as the systemic relapse dominates local tumor 
control by RT and survival benefit is not noted. 
Palliative RT in contrast to radical treatment should weigh the anticipated toxicity against 
potential benefit in treating the patient whereas radical treatment aims in eradicating the 
disease in spite of treatment associated morbidity.  
The side effects of radiation therapy depend mainly on the radiation dose given.  
 Dry mouth 
 Tooth decay 
 Sore throat or mouth 
 Sore or bleeding gums 
 Infection  
 Delayed healing after dental care 
 Jaw stiffness 
 Denture problems 
 Changes in the sense of taste and smell 
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 Changes in voice quality 
 Changes in the thyroid 
 Skin changes in the treated area 
 Fatigue
23
 
Chemotherapy: Chemotherapy uses anticancer drugs to kill cancer cells. It is called 
systemic therapy because it enters the bloodstream and can affect cancer cells throughout 
the body.
23
 In head and neck cancers, neoadjuvant chemotherapy is indicated in the setting 
of a locally advanced disease and there is an expanding role of primary chemotherapy in 
advanced disease. The primary indication of CT in head and neck cancers are metastatic 
disease and in locally advanced disease, it is used as induction therapy to help to reduce 
tumour burden and to proceed with surgery.
22
 In early disease CT has no much role as the 
local tumour burden is amenable either to surgery or RT.  
Initially single agent CT was used for head and neck cancers. Various chemotherapeutical 
agents were used in this setting and their efficacy tested. But single agent CT did not show  
any significant increase in survival, including taxanes. The most commonly used drugs 
were methotrexate and cisplatin. The various drugs and their dosages in single agent CT 
are as follows
22
 
Inj Methotrexate 40 -60 mg/m
2  
intravenously once every week 
Inj Cisplatin 75- 100 mg/m
2
  intravenously once every  3 -4 weeks 
Inj Paclitaxel 135 – 225 mg/m2 intravenously for 3 hours once every 3 weeks 
Inj Docitaxel 60 -100 mg/m
2
 intravenously for 3 hours once every 3 weeks 
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The various other drugs used as single agent CT are Carboplatin, 5 Flurouracil, EGFR 
inhibitor Cetuximab and tyrosine kinase inhibitors Erlotinib and Geftinib. 
Since the role of single agent CT was disappointing in disease control and improving 
survival, combination chemotherapy came in to practice. Most of combination CT 
regimens consider Cisplatin to which are added other chemotherapeutic agents. 
Combination CT has shown improvement in the form of improved survival when 
compared to single agent CT both statistically and clinically and has been confirmed by 
the ECOG group [Eastern Co operative Oncology Group]. 
22
 CT being a systemic form of 
treatment has various side effects, some related to systemic treatment and others particular 
to each chemotherapeutic agent. And side effects are common with combination 
chemotherapy when compared to single agent CT. 
Combination CT of Docetaxel and Cisplatin has shown response rate of 40 – 53% with CR 
of 16 – 18%. Cisplatin and 5 FU combination has also showed similar response rate. The 
addition of Interferon alpha 2b to the above combination did not improve the survival rate. 
Paclitaxel in the dose of 80 mg/m
2
 with Carboplatin 175 – 200 mg/m2 area under curve 2 
[AUC 2] over 3 hours with Carboplatin AUC 6 has improved survival rate in advanced 
head and neck cancers.The study of single agent Cisplatin Vs Cisplatin along with 
Cetuximab has shown definite improvement in overall survival. 
The combination of CT and RT in the form of concurrent CT and RT has improved 2 year 
survival rate to more than 20%. Sequential RTOG studies has proved the same and the 
most commonly used regimen is  
Paclitaxel 20 mg/m2 intravenously + Cisplatin 15 mg/m2 intravenously + RT 60 Gy with 
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1.5 Gy fractionation twice daily along with Granulocyte Colony Stimulating Factor. 
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Determination of response to Chemotherapy 
WHO Change in Sum of Products 
22
 
Complete response[CR] – Disappearance of all target lesions without any residual lesion 
confirmed at 4 weeks 
Partial response[PR] – 50% or more reduction in size target lesions without a 25% 
increase in any one of target lesion confirmed at 4 weeks 
Stable disease – When neither PR or progressive disease [PD] criteria are met 
Progressive disease[PD] – 25% or more increase in size of measurable lesion or 
appearance of a lesion 
RECIST Change in Sum Longest Diameter 
22
 
CR – disappearance of all target lesions confirmed at 4 weeks 
PR – At least 30% reduction in the sum of longest diameter of target lesions confirmed at 
4 weeks taking baseline study as reference 
Stable disease - When neither PR or progressive disease [PD] criteria are met, taking as 
reference the smallest sum of the longest diameter recorded since treatment started 
PD - At least 20% increase in the sum of longest diameter of target lesions, taking as 
reference the smallest sum of the longest diameter recorded since treatment started or 
appearance of new lesions 
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AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
1. To study the common sites of involvement in various subgroups 
2. To correlate FNAC and biopsy results in oral cavity lesions 
3. To study the various clinical and histopathological factors implicated in 
prognostication of oral malignancies 
4. To  study the impact of histopathological grading on treatment and  predictors 
of advanced disease  
5. To evaluate the response to treatment of oral malignancy with special 
reference to radiotherapy and chemotherapy 
6. To compare early and late oral malignancies and their response to treatment 
7. To study oral cavity malignancy with special interest towards synchronous and 
metachronous head and neck malignancies 
 
  
48 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
     Patients of oral malignancy admitted in TvMCH during the period from February, 2011 to 
August, 2012 has been considered as the study group, as per the inclusion and exclusion 
criteria given below 
Inclusion criteria:   Age > 18 years 
                       Previously diagnosed as a case of oral malignancy and on treatment 
                       Patients with synchronous and metachronous head and neck 
malignancies 
Exclusion criteria:   Age < 18 years 
                                 Known serious medical comorbidities 
                          Pregnancy  
                         Major surgery within 14 days prior  
Design of study: Prospective analysis of case series 
Sample size: 98 
   Patients were evaluated based on questionnaires and the records were scrutinized for 
relevant clinical, pathological and treatment protocols.  
  The various indicators which are under study are: age, sex, demographic data, risk factors, 
immune status, macroscopic appearance, size of lesion, surrounding induration, bony 
involvement, depth of invasion, regional lymph nodal involvement.  
   A thorough history, clinical examination and investigations are carried out and patients are 
staged, treated and followed up during the study period. Histopathological grading and 
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adequate resection margins are taken into consideration. Operative morbidity and mortality, 
various chemotherapeutic agents, radiation and their serious adverse effects, if any, are 
recorded. 
   Samples (FNAC, biopsy- excision and wedge) are taken and are sent to pathology 
department for histopathology. 
Treatment protocol in TvMCH 
Surgical-            Wide local excision with or without neck dissections 
                           Wide local excision with reconstruction using flaps 
Radiotherapy-    Curative  - 50-70 Gy in 200 # for 30 cycles 
                           Palliative tailored according to the patient [40-45Gy] 
Chemotherapy- Cisplatin based chemotherapy [50- 70mg/m
2
 every 3 weeks] 
Outcome measures  
    The outcome is being evaluated with the following parameters 
 Locoregional control 
 Development  of second malignant neoplasm/ recurrence 
 
Statistical analysis 
    The statistical analysis of the data is being done by using measures of central tendency 
(mean, median, mode) Chi-square test and data packages in case, if required. 
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National significance 
   Malignancies of head and neck, especially that of oral cavity is common in the Indian sub-
continent which is in advanced stage at the time of diagnosis with a poor 5 year survival rate. 
Prognostication of factors in malignancies helps in systematic approach and sheds light 
towards grey areas. 
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RESULTS 
Table 1   Age distribution 
Age( yrs ) 30-39 40-49 50-59 60-69 70-79 80-89 total 
Study 6 15 27 29 20 1 98 
L. P. 
Dragomir 
et al
1
 
4 13 31 45 22 2 117 
 
Figure 15 Age distribution 
The maximum number of patients belonged to the age group of 60- 69 years in both study 
group and L.P. Dragomir et al. Most of the patients fall in the age group of 50 – 79 years 
which is 76 in study group and 98 in L.P. Dragomir et al. 
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Table 2     Macroscopic type 
Type Ulcerative Ulceroproliferative Proliferative Infiltrative  
Study 43 36 4 15 98 
L. P. 
Dragomir 
et al
1
 
48 24 31 14 117 
 
 
Figure 16 Macroscopic type 
In morphology of the lesion, ulcerative was the commonest variety [43%] found in both the 
study group and L. P. Dragomir et al [41.02], which was followed by ulceroproliferative type 
[37%].  
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Table 3   Dimensions of lesion 
Size( cm ) < 2  2-4 >4(T3) >4(T4)  
Study 24 71 0 3 98 
L. P. Dragomir 
et al
1
 
11 31 15 7 64 
 
 
Figure 17. Dimensions of lesion  
T2 lesions were found to be predominating in both the study group [73%] and L. P. Dragomir 
et al [48%], followed by T1 lesions [24%]. 
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Table 4   Sex distribution 
Sex Male Female  
Study 72 26 98 
L. P. Dragomir et al
1
 105 12 117 
 
Figure 18 Sex distribution 
Gender is not a risk factor in the development of oral malignancies, but is commonly seen 
due to the fact that risk factors in oral malignancy are seen more in males. Males constituted 
about 70% of study and 89% of L. P. Dragomir et al group. 
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Table 5   Risk factors 
Risk 
factors 
Smoking Alcoholism Pre-
existing 
lesions 
Tobacco 
chewing 
STD FH Associations 
Study 56 24 86 49 - - 92 
L. P. 
Dragomir 
et al
1
 
11 7 5 - - 1 21 
 
Figure 19 Risk factors 
Smoking was seen in 57% of study group, while other associated risk factors tobacco 
chewing and alcoholism were seen in 50% and 24% of study group respectively. The 
association between various risk factors was up to 92%.  
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Table 6    Localisation of lesion 
Localisation Lip  Cheek  Tongue  Gingiva  RMT Hard 
palate 
Floor of 
mouth 
 
UL LL Angle Rt  Lt  Rt  Lt  Rt Lt Rt Lt 
Study 2 1 2 22 14 17 18 1 2 1 3 11 4 98 
5 36 35 3 4 11 4 
L. P. Dragomir 
et al
1
 
41 - 38 26 - 5 7 117 
 
Figure 20 Localisation of lesion 
Cancer buccal mucosa and tongue were the commonest types accounting to 37% and 36% 
respectively in the study group comprising 71% of overall oral cancers. Whereas in L. P. 
Dragomir et al group, cancer lip [35.04%] was followed by tongue [32%]. This is probably 
explained by the fact that in the Indian scenario, tobacco chewing is more common when 
compared to Western World.  
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Table 7   Differentiation  
Differentiation Well differentiated Moderately 
differentiated 
Poorly 
differentiated 
 
Study 45 27 26 98 
L. P. Dragomir et al
1
 44 32 42 118 
 
Figure 21 Differentiation 
In both study and L. P. Dragomir et al groups, well differentiated tumours were common to 
the tune of 45% and 37% respectively.  
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Table 8   Tumor progression 
Progression  Microinvasive 
carcinoma 
Invasive carcinoma without 
nodal metastasis 
Invasive carcinoma 
with nodal 
metastasis 
 
Study - 19 79 98 
L. P. 
Dragomir et 
al
1
 
2 57 3 62 
 
Figure 22 Tumor progression 
Invasive cancer with nodal metastasis was common in the study group [80%], probably 
owing to the late presentation of cancers. 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
Microinvasive 
carcinoma 
Invasive 
carcinoma 
without nodal 
metastasis 
Invasive 
carcinoma with 
nodal metastasis 
Study 
L. P. Dragomir et al 
61 
 
 
Table 9    Treatment 
Treatment Radiotherapy Surgery(S) Chemotherapy Combined Symptomatic  
 78 5 10 4 
S + RT 3 
CT + RT 1 
1 
 79% 5% 10% 4% 1% 
 
 
Figure 23 Treatment 
Most of the cases are treated in TvMCH by RT.  Hence the study group has received RT to 
the tune of 80%. 
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         Table 10           Resected margins (Total no of surgical cases  8) 
Margins Free of tumor Involved by 
tumor 
 
Study 5 3 8 
L. P. Dragomir et al
1
 12 13 25 
 
 
Figure 24 Resection margins 
Of the eight patients taken up for surgery, five had margins free of tumour.  
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Individual statistics 
Table 11   Age distribution - lesion wise- Most of cases belonged to 50 – 79 years 
with the exception of tongue where maximum cases were in 40 – 49 year age group. 
Age(yrs) 30 - 39 40 -49 50 -59 60 -69 70 – 79 80 - 89 No 
Lip - 1 2 2 - - 5 
Cheek 3 3 8 12 10 - 36 
Tongue 2 10 9 8 6 - 35 
Hard palate 1 1 3 4 2 - 11 
RMT - - 2 1 1 - 4 
Gingiva - - 1 - 1 1 3 
Floor of mouth - - 3 1 - - 4 
 
Table 12    Macroscopic type – lesion wise- Most of cheek lesions were 
ulceroproliferative, tongue lesions were ulcerative and hard palate infiltrative. 
Type Ulcerative Ulceroproliferative Proliferative Infilterative No 
Lip 2 2 1 - 5 
Cheek 1 31 3 1 36 
Tongue 29 2 1 3 35 
Hard palate 2 1 - 8 11 
RMT 1 - - 3 4 
Gingiva 1 2 - - 3 
Floor of mouth - 1 - 3 4 
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Table 13    Dimensions - lesion wise- Most cases belonged to T2 group [2-4 cm]. 
Dimensions < 2 cm 2 – 4 cm  T3 T4 No 
Lip 5 - - - 5 
Cheek 2 30 1 3 36 
Tongue 9 26 - - 35 
Hard palate 5 6 - - 11 
RMT 1 3 - - 4 
Gingiva 1 2 - - 3 
Floor of mouth 1 3 - - 4 
Table 14    Sex distribution - lesion wise- Sex predilection was seen for Cancer tongue and 
Cancer hard palate. 
Sex  Male Female No 
Lip 3 2 5 
Cheek 20 16 36 
Tongue 31 4 35 
Hard palate 8 3 11 
RMT 3 1 4 
Gingiva 3 - 3 
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Floor of mouth 4 - 4 
 
Table 15     Risk factors – lesion wise- Main risk factors were Smoking and tobacco chewing. 
Risk factors Smoking Alcoholism Lesions  Tobacco chewing STD Associations 
Lip 3 3 4 2 - 1 
Cheek 18 6 35 20 - 36 
Tongue 21 10 30 13 - 35 
Hard palate 6 1 6 7 - 7 
RMT 3 2 3 2 - 4 
Gingiva 3 1 3 1 - 3 
Floor of mouth 4 1 3 - - 4 
Table 16     Differentiation - lesion wise- Most cases were well differentiated but for 
retromolar trigone where poorly differentiated variety was seen commonly. 
 Differentiation  Well  Moderate Poor No 
Lip 4 - 1 5 
Cheek 19 9 8 36 
Tongue 16 11 8 35 
Hard palate 3 3 5 11 
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RMT - 1 3 4 
Gingiva 1 - 2 3 
Floor of mouth 2 2 - 4 
Table 17       Tumour Progression - lesion wise- Most cases had nodal metastasis. 
Progression  Invasive carcinoma with no 
nodal metastasis 
Invasive carcinoma with 
nodal metastasis 
No 
Lip 1 4 5 
Cheek 1 35 36 
Tongue 3 32 35 
Hard palate 11 - 11 
RMT 1 3 4 
Gingiva 1 2 3 
Floor of mouth 1 3 4 
 
Table 18      Treatment - lesion wise 
Treatment   RT Surgery(S)  CT Combined Symptomatic No 
Lip 3 1 - - 1 5 
Cheek 29 4 2 1 
S + RT 
- 36 
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Tongue 28 - 5 2 
S + RT 
CT + RT 
- 35 
Hard palate 9 - 2 - - 11 
RMT 4 - - - - 4 
Gingiva 3 - - - - 3 
Floor of mouth 2 - 1 1 
S + RT 
- 4 
 
Table 19     Resected margins (surgical cases 8) - lesion wise- Cancer cheek had high tumor 
free margins. 
Treatment  Free of tumor Involved by tumor Percentage  
Of surgical cases 
Lip 1 - 20% 
Cheek 4 1 13% 
Tongue - 1 2% 
Hard palate - - 0% 
RMT - - 0% 
Gingiva - - 0% 
Floor of mouth - 1 25% 
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 Table 20      Staging – lesion wise 
Treatment  I II III IV No 
Lip 1 - 4 - 5 
Cheek 1 - 8 27 36 
Tongue 3 - 17 15 35 
Hard palate 5 6 - - 11 
RMT - 1 3 - 4 
Gingiva - 1 1 1 3 
Floor of 
mouth 
1 - 2 1 4 
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Table 21            History  
 Pre ex 
isting 
Lesion 
Toothlo
ss 
Swallowi
ng 
Difficult
y 
Salivatio
n 
Bleeding Difficult
y-mouth 
opening 
Weight 
Loss 
Smokin
g 
Tobac
co 
Chewi
ng 
 
 
 
Lip 4 - - 1  2  2  - 3 3 2 
Cheek 35  6  12  14  17  15  2  18  20  6  
Tongue 30  5  13  24  15  4  - 21  13  10  
Hard 
palate 
6 - - 3  1  - 
 
- 6 7 1 
RMT 3 - 4 4 - - - 3 2 2 
Gingiva 3 3 - - 3  - - 3 1 1 
Floor of 
mouth 
3 1  2  3  1  - - 4  1  - 
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Subsites in oral cavity 
Table 22      Lip (Cases: 5) – Early lesions had CR when compared to late lesions. 
No of 
cases 
Stage Response Smoking 
 
 Differentiated Tobac
co 
Complete Partial No 
Response 
Alcoholism Well Mod Poor 
1 I 1 - - 1 1 1 - - - 
- II - - - - - - - - - 
4 III 1 2 1 2 2 3 - 1 - 
- IV - - - - - - - - - 
 
Table 23     Cheek (Cases: 36) – More lesions were late lesions and the response was partial.  
No of 
cases 
Stage Response   Differentiated  
Compl
ete 
Partial Recurre
nce  
Smoking Alcoholism Well Mod Poor Tobacco  
1 I 1 - - 1 - 1 - - 1 
- II - - - - - - - - - 
8 III 2 6 - 5 1 5 2 1 5 
27 IV 2 24 1 12 3 13 7 7 18 
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Table 24      Tongue (Cases: 35) - More lesions were late lesions and the response was partial. 
No of 
Cases 
Stage Response   Differentiated Tobacco 
Complete Partial Smoking Alcoholism Well Mod Poor  
3 I 2 1 2 - 3 - - 3 
- II - - - - - - - - 
17 III 2 15 11 7 7 6 4 6 
15 IV - 15 13 4 6 5 4 5 
 
Table 25       Hard palate (Cases: 11) – Most of the lesions were early and the 
response being good. 
No of 
Cases 
Stage Response   Differentiation Tobacco 
Complete Partial Smoking Alcoholism Well Mod Poor 
5 I 4 1 4 1 3 - 2 3 
6 II 6 - 4 - - 3 3 3 
- III - - - - - - - - 
- IV - - - - - - - - 
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Table 26      Retromolar trigone (Cases: 4) – Most cases were poorly differentiated and 
response being partial. 
No of 
Cases 
Stage Response   Differentiation Tobacco 
Complete Partial Smoking Alcoholism Well Mod Poor 
- I - - - - - - - - 
1 II - 1 1 - - 1 - 1 
3 III - 3 2 2 - - 3 1 
- IV - - - - - - - - 
 
Table 27      Gingiva (Cases: 3) – Late lesions had Partial Response. 
No of 
Cases 
Stage Response   Differentiation Tobacco 
Complete Partial Smoking Alcoholism Well Mod Poor 
- I - - - - - - - - 
1 II 1 - 1 1 - - 1 - 
1 III - 1 1 - 1 - - 1 
1 IV - 1 1 - - - 1 - 
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Table 28     Floor of mouth (Cases: 4) – Late lesions had less favorable outcome. 
No of 
Cases 
Stage Response   Differentiation Tobacco 
Complete Partial Smoking Alcoholism Well Mod Poor 
1 I 1 - 1 1 - 1 - - 
- II - - - - - - - - 
2 III 1 1 2 - 2 - - - 
1 IV - 1 1 1 - 1 - - 
 
 Table 9              TREATMENT 
Treatment Radiotherapy Surgery(S) Chemotherapy(CT) Combined Symptomatic  
No 78 5 10 4 
S + RT 3 
CT + RT 1 
1 
 
Chemotherapy : 10 cases 
                             Two cases of Ca cheek  – stage IV 
                             Five cases of Ca tongue –   four   stage III   
                                                                          one stage IV 
                             Two cases of Hard palate 
                             One case of Floor of mouth 
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Combined treatment modality   -   Four 
Surgery + Radiotherapy    - Three cases       -Ca tongue ( stage I ) 
                                                                       Ca cheek ( stage IV ) 
                            Ca floor of mouth ( stage III ) 
Radiotherapy + Chemotherapy-  One case of  Ca tongue ( stage IV ) 
Surgery     -   Eight  
Ca tongue         One    stage I 
Ca lip        One    stage I 
Ca cheek        Four - 3 cases of stage III and one stage IV 
Ca cheek/lip             One   stage IV 
Ca Floor of mouth      One  stage III 
Recurrence 
 One case of Ca cheek stage IV       After one month of surgery + RT 
Synchronous malignancy 
One case of Ca lip/cheek                Stage IV 
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Table 29       TREATMENT OUTCOME 
OUTCOME NUMBER OF CASES PERCENT 
Complete relapse          24   24% 
Partial relapse          72   73% 
No response           1     1% 
Recurrence            1     1% 
Synchronous malignancy           1     1% 
 
Complete relapse was seen in 24 cases and partial relapse in 72 cases. 
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DISCUSSION 
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DISSCUSSION 
Localization of lesion  
Oral malignancies after diagnosis is broadly categorized based on the anatomical location. Of 
the 98 patients taken up under the study, the majority belonged to Carcinoma buccal mucosa 
[36 patients-36%] and carcinoma tongue [35 patients- 35%] making up to 72% of the study 
group. Carcinoma alveolus/gingiva forms the lowest cohort [3 patients- 3%].  
In contrast in L. P. Dragomir et al
1
 group, cancer lip [41 patients-35.04%] and tongue [38 
patients-32.47%] had higher incidence compared to other regions with an overall percentage 
of 67.52% with hard palate forming lowest cohort [5 patients- 4.2%]. 
 The difference can probably be explained by the high incidence of betal nut [tobacco] 
chewing in India and increased exposure to sun light in the reference group [L. P. Dragomir 
et al
1
]. 
Patel MM and Pandya AN
24
 studying oral and oropharyngeal cancers have reported the 
commonest site as oral tongue [23.02%], followed by posterior third tongue [19.64%], 
alveolus, lips and cheek. 
Mehrotra Ravi et al,
25
 in their study, cancer tongue was the most common sub site with 129 
cases [42.57%] of followed by the cheek in 58 [19.14%].   
Iype EM et al,
26
 has reported that the commonest site in oral cancer is tongue cancer at 52% 
followed by buccal mucosa [26%], alveolus [10%], palate [4.5%], lip [2.3%] and floor of 
mouth forming the least common variety [1.9%]. 
Khandekar SP et al,
27
 have showed alveolus as the commonest site of presentation with 55% 
of cases. In Ahluwalia et al
28
 in the year 2001, carcinoma cheek was the common oral 
malignancy at 55.60% followed by oral tongue at 31.41%. 
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The study shows similar distribution of cancer in various sites when compared to Indian 
studies. Cancer cheek and tongue cancer have almost similar presentation rates, 36% and 
35% respectively.  
Sex  
The sex ratio in the study group and L. P. Dragomir et al
1
 group has clearly demonstrated the 
male preponderance in oral malignacies and head and neck cancers in general with male 
preponderance being 73% and 89.74% respectively. 
Table 30 Sex distribution in various studies 
Study  Male [%] Female [%] 
Patel MM et al
24
 75 25 
Mehrotra et al
25 
76.57 23.43 
Iype et al
26 
70 30 
Dhar PK et al
29 
68.3 31.7 
Khandekar et al
27
 61.25 38.75 
 
Sex is not a risk factor for the development of oral cancers in males
32
. The difference in 
gender is due to high rate of smoking and alcoholism in males. Also tobacco chewing is also 
high among men in the Indian sub continent. The study has shown the male population is 
more affected similar to various studies reported in India as mentioned in the table. 
Age  
The age group between 50-79 years had the highest incidence of cases [76 patients] with a 
percentage of 77% which is similar to the study conducted by L. P. Dragomir et al
1
 with the 
incidence of 98 out of 117 cases in similar age group [83.76%].  
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The youngest age of presentation in the study group is 30 year old female with carcinoma 
oral tongue stage III and the oldest age was 82 year old male with stage III cancer gingiva. 
Only six percent were less than 40 years belonging to the age group 30 – 39 years. 
The maximum number of patients belonged to the age group of 60- 69 years in both study 
group [29 cases- 29%] and L.P. Dragomir et al group
1
 [38.46%], which was followed by 27 
cases in the age group 50 – 59 years and 20 cases in 70 – 79 year group. 
Patel MM et al
24
 have reported in his study on oral and oropharyngeal cancers, 12.9% of 
cancers below 35 years, 23.8% of cases between 35 – 45, and 63.3% cases over the age of 45 
years. 
Mehrotra Ravi et al,
25
 in a study on oral cancer, has reported that the maximum incidence was 
in the age group 50 – 59 years. Iype et al has reported an incidence of 2.8% of cases before 
the age of 35years. Dhar PK et al
29
 reported maximum incidence [35.7%] in the age group of 
51- 60 years. 
Since most of the studies show that that the incidence of oral cancer is more after the age of 
50 years, targeting screening programmes to males over 50 years with smoking can detect 
cancers at an early stage.  
 Morphology of lesion 
In gross morphology, the study group had more number of ulcerative [43%] and 
ulceroproliferative [36%] types when compared to infiltrative [15%] and proliferative [4%] 
types making up to 80% of lesions. Whereas in L. P. Dragomir et al group
1
, due to more 
proliferative [26.49%] type lesions, ulcerative [41.02%] and ulceroprolifertive [20.51%] 
types constituted to about 61.53%.  
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The difference is due to high incidence of cancer lip in the reference population, which has 
proliferation as the common morphological pattern. 
Size of lesion 
With respect to the size of the lesion, T2 lesions[ 2-4 cm ] constituted the largest group in 
both study and L. P. Dragomir et al
1
 group making 72% and 48% respectively followed by 
T1 lesion[less than 2 cm]  in study and T3 lesion[ more than 4 cm resectable lesion] in L. P. 
Dragomir et al group.
1
 
Size of the lesion determines treatment outcome and also the choice of surgery.
31
 Only 
tumour depth and grade is associated with lymphnodal spread. Tumor size [diameter] and 
margins predicts local recurrence.
30
  
Hence the size as well as the depth of the lesion helps in prognosticating the disease.
30
 
Tumour Type and Differentiation  
All cases in the study group were found to be of squamous cell origin similar to various 
studies conducted on oral cancers. 
Table 31  Tumour Type in various studies 
Study  Percentage of SCC[%] 
Patel MM et al
24
 100 
Mehrotra et al
25
 100* 
Alhuwalia et al
28
 92.56 
Iype EM et al
26
 72 
Khandekar et al
27
 72.5 
*all the malignant cases confirmed by biopsy were SCC with varying grades. Benign & premalignant lesions 
were also part of study. 
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In differentiation of tumors, study group showed well differenciated category as the major 
subset, with a percentage of 46% followed by moderately and poorly differentiated varieties 
at 27% and 26% respectively, whereas L. P. Dragomir et al
1
 group showed no clear 
distinction between the subsets, well differenciated constituting to about 37.28% followed by 
poorly and moderately differentiated at 35.59% and 27.11% respectively. 
Patel MM et al
24
 study has shown differentiation of tumours for well, moderate, and poorly 
differentiated varieties to be 60.12%, 38.7%, and 8.9% respectively. 
Mehrotra Ravi et al
25
 study, of the 303 malignant cases, the differentiation rates for well, 
moderate and poorly differentiated varieties are 56.76%, 41.91% and 1.3% respectively. 
Khandekar et al
27
 study has shown the rates of well, moderate and poorly differentiated 
varieties to be 33.75%, 20% and 18.75% respectively, with verrucous carcinoma at 27.5%. 
Iype EM et al
26
 has shown the rates of well, moderate and poorly differentiated varieties to be 
52.6%, 34.2% and 4.2% respectively, undifferentiated being the rest. 
Tumor progression  
In tumor progression, study group showed that the subset invasive carcinoma  with nodal 
metastasis constitutes 80% in contrast to L. P. Dragomir et al
1
 group, in which, the cohort of 
invasive carcinoma without nodal metastasis had a percentage of 91%. 
This is probably accountable to the late stage of presentation in the Indian sub continent. 
Resection margins 
In surgical cases, the number of negative margins in study group was 62% and in L. P. 
Dragomir et al
1
 group, negative mergins were achieved in only 48% of cases. 
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The role of resection margins cannot be considered as the number of surgical cases in both 
the study and  L. P. Dragomir et al
1
 group is small to be statistically significant. 
The site specific details of oral malignancies have been mentioned in the charts. 
Out of 98 cases, eight cases were taken up for surgery, all of which were well differentiated. 
Table 32 List of surgical cases 
Lesion  Stage  Differen 
tiation 
Resection 
margins 
Response Adjuvant 
therapy 
Recurrence   
Tongue  I Well  Involved  PR RT - 
Lip   I Well  Free CR - - 
Cheek  IVa Well  Involved   PR RT + 
Cheek  III Well  Free  CR - - 
Cheek  III Well  Free  CR - - 
Cheek  IVa Well  Free  CR - -  
Cheek/lip IVa Well  Free  CR - - 
Floor of 
mouth 
 III Well  Involved  CR RT -  
 
Table 9      Treatment 
 
No  Radiotherapy(RT) Surgery(S) Chemotherapy(CT) Combined Symptomatic  
98 78 5 10 4 
S + RT 3 
CT + RT 1 
1 
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Iype et al
26
, in their study, have given the following treatment. 
Table 33   Iype et al treatment protocol 
Treatment  RT Surgery  Surgery + RT CT + RT Palliative/no Rx   
No  96 21 45 38 43 264 
 
RT as primary modality in 36.6% [96], RT followed by surgery in 8% [21] , CT and RT in 
14.3% [38], surgery with adjuvant RT in 17% [45] and the lowest cohort of 8% [21] by 
surgery only.   
A case of recurrent cancer was seen in a 55 year old male with cancer Rt cheek, stage Iva 
who underwent wide excision with forehead flap followed by RT for positive margins 
following resection. Recurrence was seen five months following RT. 
A case of synchronous malignancy was seen in 71 year old male cancer Lt cheek/lip, stage 
IVa who underwent wide local excision with forehead flap. Patient had complete response. 
Of the 10 cases who underwent chemotherapy, two cases had complete response- floor of the 
mouth cancer stage I and hard palate cancer stage II. 
Of the four cases with combined modality treatment, one patient had complete response- 
floor of mouth stage III, who underwent wide local excision along with RT. Of the other 
cases, one patient had recurrence- carcinoma cheek stage IVa five months after surgery and 
RT and two had partial responses. 
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Risk factors 
Tobacco and alcohol intake 
Oral malignancies is a disease of middle aged and old aged male smokers. This has been  
evidently in the study group. The male preponderance in the study group is up to 73% and 
significant smoking history is associated in 57% of study group and tobacco chewing is seen 
in up to 50% of them. Tobacco chewing is associated in most of the women with oral 
malignancies to the tune of 100% and in about 47% males, mostly non smokers. Alcohol 
intake was seen in 24% of study group. 
Smoking was not seen in the study group containing females.  
In Iype et al study
26
, 59.4% of patients had history of tobacco chewing or smoking or alcohol 
intake.  
Khandekar et al
27
 have shown in their study that tobacco chewing is seen in is seen in 71.3% 
and smoking in about 63.3%.  
Other risk factors: No patients under study had STDs or HPV infection. Asssociations 
between risk factors were seen in 94% of study group and pre existing lesions in about 88%.  
 
Tables  34 & 35 Comparison between early [stages I and II]  and late lesions [stages III 
and IV]  
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  Early lesions                                                            Late lesions 
        CR          PR            CR             PR No 
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21 
 
   1 
WD 
 
1 
WD 
       
      16 
  
          3 
   
         8 
 
 
69 
 
 1 
 
 1 
  
Tumour grade and tumour depth are important criteria for nodal metastasis
30
. But in the study 
group, 75% of poorly differentiated tumours had nodal metastasis in contrast to 80% in well 
and in moderately differentiated tumours. 
In the study group, late stages of disease [stages III and IV] compromised up to 80% of study 
group, in contrast to 66.3% in Iype et al
26
. Nodal involvement was seen in 51.9% in Iype et al 
and in about 80% in the study group.  
According to the study group, early lesions had more CR than late lesions.  
Table 36  Response to treatment based on Differentiation 
         PD       MD               WD 
CR PR CR PR CR PR No 
response 
Recurrence 
  
5 22 5 21 14 29 1 
 
1 
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The reasons for late presentation of oral malignancies has been explained by Sandeep Kumar 
et al
33
 and the might hold good for the late presentation of the same in the study group. 
The percentage of CR in well differentiated, moderately differentiated and poorly 
differentiated lesions is 31%, 19% and 19% respectively. 
 Table 29   TREATMENT OUTCOME 
OUTCOME NUMBER OF CASES PERCENT 
Complete relapse          24   24% 
Partial relapse          72   73% 
No response           1     1% 
Recurrence            1     1% 
Synchronous malignancy           1     1% 
 
Table 37  Sitewise Response to treatment – Hard palate had more CR than other sites. 
Site  CR PR No response Recurrence  No  
Lip  2 2 1 - 5 
Cheek  5 30 1 1 36 
Tongue  4 31 - - 35 
Hard palate 10 1 - - 11 
RMT - 4 - - 4 
Gingiva 1 2 - - 3 
Floor of mouth 2 2 - - 4 
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Prognostication in oral malignancies is based on stage and grade of the disease, of which 
stage is indirectly determined by 
1. Size of the lesion 
2. Involvement of adjacent structures [T3], which is resectable but chances of more 
chances of left over tumor  
3. Involvement of base of skull, pterygoid plate, masticator space, or encasement of 
carotid artery [T4], which is inoperable  
4. Presence or absence of lymph nodal/ distal metastasis6,30 
Prognosis of oral malignancy is affected by the grade of tumors as nodal spread is common 
with moderately and poorly differentiated tumors, and the same has been demonstrated by the 
study group.
30
 
Independently, tumour depth and grade are strong prognostic factors for nodal metastasis and 
tumour size and margins helps to predict local recurrences in the oral cavity independently of 
one another.
30
 
Clinical factors in prognostication of oral malignancy 
Table 38   Clinical factors in prognostication of oral malignancy 
 Age  Sex  Lesion  Smoking  Alcohol  Tobacco  
<49 >49 M F + _ 20p + - + - + - 
Early lesion 5 14 16 3 13 6 11 4 4 4 15 12 7 
Late lesion 16 63 56 23 74 5 44 11 24 19 60 38 41 
 
26% of early lesions occurred in younger age group compared to 20% in late lesions. 
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Sex is not a risk factor for the development of oral cancer.
31
 It has been considered here due 
to high incidence of oral cancers in males. In early lesions, up to 84% of cases is seen in 
males whereas in late lesions, it is seen only up to 70%. This can be probably explained by 
comparatively early medical attention seeking in males compared to females. 
Pre existing lesions are seen in 68% in early lesions when compared to 94% in late lesions. 
Hence screening programmes if properly implemented may help to detect early lesions. 
 Significant smoking history is seen in 57% in early lesions and in 56% in late lesions. 
Tobacco chewing is seen in 63% of early lesions to 48% of late lesions. 
Alcohol intake history is seen in 21% of early lesions to 24% of late lesions. The low 
incidence of alcohol intake history is probably due to improper alcohol intake history given.  
Table 39  Site wise prognostication – Hard palate had more early lesions. 
 Early lesion Late lesion No 
Lip  1 4 5 
Cheek  1 35 36 
Tongue  3 32 35 
Hard palate 11 - 11 
Retromolar trigone 1 3 4 
Gingiva 1 2 3 
Floor of mouth 1 3 4 
 
As the study is a descriptive type of study, chi square test and P value could not be used to 
determine the significance of the study.   
89 
 
CONCLUSIONS 
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CONCLUSIONS 
Oral malignancies is predominantly seen in males though sex is not a risk factor 
Mainly affects old male smokers, but younger age of onset may be seen which should be 
thoroughly evaluated 
Tobacco and alcohol consumption are two most important risk factors 
Association between various risk factors in not only additive but also synergistic 
Cheek and tongue have almost similar rates of involvement 
Well differentiated SCC is the most common histological variety 
Most common morphologic type being ulcerative 
Size of the lesion and resection margins important prognostic factors in determining local 
recurrences 
Grade of the tumour did not have a role in determining nodal spread in the study group 
One case each of synchronous malignancy [cheek and lip] and recurrent cancer cheek, though 
statistically small can explain the concept of field cancerization  
Early lesions have good response to treatment either in the form of RT or Surgery 
Though stage of the disease is the major determinant of response to treatment independent of 
grade of tumour 
Nodal disease has a bearing in the response rate and treatment option 
More early lesions are found in males when compared to females probably due to early 
seeking of medical attention. Pre existing lesions were seen predominantly in the late lesions 
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MASTER CHART 
Guide to Master Chart 
WD      Well Differentiated                       
MD       Moderately Differentiated                                               
PD         Poorly Differentiated                   
UP    Ulceroproliferative   
U      Ulcerative     
I        Infiltrative        
P        Proliferative                                                                                                                   
Early – Early lesion – Stages I, II 
Late – Late lesion - Stages III, IV 
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sl no name ip no age sex socioeconomic statuspre exis ing lesionsmoking alcoholismtobacco STD size LN macroscopic typebiopsy stage diagnosis treatmentresponse e/l
1 mangalakannan8882 50 M low + 30p - - - 3*2 N1 UP WD III floor of mouthS + RT Complete late
2 tirikesh 13585 49 M low + 30p 1/d - - 1*1 N1 P WD III angle of mouthRT Partial late
3 perumal 15096 55 M low + 35p 1/d - - 3*2 N2c I MD IVa floor of mouthRT Partial late
4 murugan 15311 50 M low - 25p 2/d + - 2*2 N0 UP WD I hard palateRT Complete early
5 balakrishnan 15316 75 M low + 10p    - +    - 3*2 N2c UP MD IVa Lt cheek RT Partial late
6 natarajan 16204 74 M low + 20p - - - 4*3 N1 UP WD III Rt cheek RT Partial late
7 arunachalam 16205 62 M low - 35p 1/d - - 2*2 N1 U PD III Lt RMT RT Partial late
8 karpusamy 16210 42 M low + 30p - + - 1*2 N0 P WD I Rt cheek RT Complete early
9 rasaiah 16236 58 M low + 20p 1/d - - 4*3 N2c U WD IVa Lt tongue RT Partial late
10 thiravium 18347 60 M low + 15p - + - 3*2 N2a U MD IVa Rt tongue RT Partial late
11 rathnam 18352 70 M low + 20p  -  +  - 5*4 N2a UP MD IVa Lt cheek RT Partial late
12 sankarammal 18359 65 F low   +  -  -  +  - 3*2 N1 UP WD III Rt cheek RT Partial late
13 palavesammal18360 55 F low  +  -  -  +  - 2*2 N1 UP WD III lower lip RT Partial late
14 chidambaram 18374 57 M low  + 25p  -  -  - 3*2 N1 I WD III floor of mouthRT Partial late
15 raiah 20807 36 M low  - 15p 1/d  +  - 3*2 N1 UP WD III Lt cheek RT Partial late
16 murugan 20875 40 M low  - 15p  -  +  - 2*1 N0 I PD I hard palateRT Complete early
17 thanuvel 22008 65 M low  + 30p 1/d  -  - 3*1 N2b P PD IVa Rt cheek RT Partial late
18 subramaniyan22268 45 M low  + 10p  -  +  - 2*1 N0 U WD I Lt tongue RT Complete early
19 petchiammal 23342 70 F low  +  -   -  +  - 4*3 N2b UP WD IVa Rt cheek RT Partial late
20 sivanammal 23333 55 F low  +  -  -  +  - 3*2 N1 UP WD III Lt cheek RT Partial late
21 saravanan 25058 62 M low  + 30p  -  -  - 3*2 N2a UP MD IVa Rt cheek RT Partial late
22 poongani 27076 60 F low  +  -  -  +  - 3*2(T4a) N2b I PD IVa Lt cheek RT Partial late
23 chellammal 28386 63 F low  +  -  -  +  - 3*2 N2a UP WD IVa Rt cheek RT Partial late
24 duraipandi 28443 82 M low  + 30p  -  +  - 2*1 N1 U WD III Rt gingiva RT Partial late
25 malaikani 29702 49 F low   +  -    -  +  - 2*2 N1 U MD III Lt tongue RT Partial late
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sl no name ip no age sex socioeconomic statuspre exis ing lesionsmoking alcoholismtobacco STD size LN macroscopic typebiopsy stage diagnosis treatmentresponse e/l
26 ganesan 29804 32 M low  + 5p  -  +  - 2*2 N0 U WD I Lt tongue RT Complete early
27 poongani 30938 66 F low  +  -  -  +  - 3*2 N2a UP WD IVa Lt cheek RT Partial late
28 gurusamy 30947 70 M low  + 30p  -  -  - 3*2 N2a U PD IVa Rt tongue RT Partial late
29 saravanan 31152 62 M low  - 25p 1/d  -  - 2*2 N0 I MD I floor of mouthCT Complete early
30 subban 15093 50 M low  + 20p 2/d  -  - 3*2 N2c U PD IVa Lt tongue RT+CT Partial late
31 saravanan 33258 60 F low  +  -  -  +  - 3*2 N2c UP MD IVa Rt cheek RT Partial late
32 mookan 34264 71 M low  + 30p  -  -  - 4*3(T4a) N2c UP WD IVa Lt cheek/lipS Complete late
33 malaikani 34477 55 M low  +  -  -  +  - 3*2 N1 U WD III Rt tongue RT Partial late
34 aanai muthukumar34480 70 M low  + 30p 1/d  -  - 3*2 N0 UP PD II Lt gingiva RT Complete early
35 pappa 38031 56 F low  +  -  -  +  - 2*3 N1 I PD III Lt RMT RT Partial late
36 mariammal 38568 47 F low  +  -  -  +  - 3*2 N2c U MD IVa Rt tongue RT Partial late
37 mani 40165 70 M low  + 20p  -  +  - 3*2 N0 I MD II Lt RMT RT Partial early
38 mani 40170 50 M low  + 10p  -  +  - 3*3 N2b I MD IVa Rt tongue RT Partial late
39 muthukumar 42366 75 M low  + 30p  -  -  - 3*2 N2b U MD IVa Lt tongue RT Partial late
40 vadivel 42393 50 M low  + 20p  -  -  - 3*2 N2a UP PD IVa Lt gingiva RT Partial late
41 peramu 42822 70 F low  +  -  -  +  - 3*3 N2a UP WD IVa Rt cheek RT Partial late
42 thangasamy 43585 48 M low  + 20p 1/d  -  - 2*3 N2b P PD IVa Lt tongue RT Partial late
43 mookayee 43626 36 F low  -  -  -  +  - 2*3 N0 U PD II hard palateRT Complete early
44 raabith 43658 75 F low  -  -  -  +  - 2*2 N0 U PD I hard palateRT Complete early
45 shanmugam 44817 60 M low  + 25p  -  -  - 3*3 N2b U WD IVa Rt tongue RT Partial late
46 sahul hameed44827 56 M low  + 20p  -  -  - 4*3 N2a UP MD IVa Lt cheek RT Partial late
47 valliammal 45276 60 F low  +  -  -  +  - 4*3 N2b UP WD IVa Rt cheek S Complete late
48 valli 46061 60 F low  -  -  -  +  - 3*2 N0 I PD II hard palateRT Complete early
49 sivanammal 46789 71 F low  +  -  -  +  - 3*2 N1 UP WD III Rt cheek S Complete late
50 velladurai 47076 55 M low  + 30p 1/d  -  - 2*1 N1 UP PD III rt angle of mouthRT Complete late
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sl no name ip no age sex socioeconomic statuspre exis ing lesionsmoking alcoholismtobacco STD size LN macroscopic typebiopsy stage diagnosis treatmentresponse e/l
51 valliappan 47078 75 M low  + 30p  -  -  - 5*4(T4a) N2b UP PD IV a Rt cheek RT Partial late
52 chellaiah 48190 65 M low  + 25p 1/d  -  - 4*3 N2a UP PD IV a Lt cheek RT Partial late
53 pandi 48337 48 M low  + 20p 1/d  -  - 3*2 N1 UP MD III Rt tongue RT Partial late
54 duraipandi 49212 50 M low  + 15p  -  +  - 3*2 N2a I MD IV a Lt tongue RT Partial late
55 ganesh 49854 47 M low  + 15p  -  +  - 3*2 N1 UP MD III Rt cheek RT Partial late
56 rajendran 51572 50 M low  + 30p 1/d  -  - 3*2 N1 I PD III Rt RMT RT Partial late
57 thangakani 52652 60 F low  -  -  -  +  - 2*2 N1 U WD III lower lip symptomaticno responselate
58 mathi 53205 55 M low  + 30p  -  -  - 3*2 N1 UP MD III Lt tongue RT Complete late
59 sankaralingam54243 65 M low  + 30p  -  -  - 2*2 N0 I WD I hard palateRT Complete early
60 dharmaraj 55557 45 M low  + 20p 1/d  -  - 4*3 N2b UP WD IV a Rt cheek RT Partial late
61 muthulakshmi55796 52 F low  +  -  -  +  - 3*2 N2a UP WD IV a Lt cheek RT Partial late
62 esakkimuthu 56204 65 M low  + 35p 1/d  -  - 2*1 N0 U WD I upper lip S Complete early
63 muthusamy 57984 60 M low  + 20p  -  -  - 3*2 N2a UP WD IV a Rt cheek RT Partial late
64 arumugam 57999 67 M low  + 30p  -  -  - 2*2 N2a U WD IV a Lt tongue RT Partial late
65 arumugam 59272 67 M low  + 15p 1/d  +  - 3*2 N1 U WD III Rt tongue RT Partial late
66 shanmugam 59714 50 M low  + 30p  -  -  - 3*2 N1 UP WD III Lt cheek S Complete late
67 manikandan 60427 42 M low  + 20p 2/d  -  - 3*2 N1 U WD III Rt tongue RT Partial late
68 arumugam 60485 70 M low  + 30p  -  -  - 3*2 N1 U WD III Lt tongue RT Partial late
69 pandi 60514 60 M low  + 30p 1/d  -  - 3*2 N2a U WD IV a Rt tongue RT Partial late
70 thangaiah 60515 60 M low  + 20p  -  -  - 3*2 N1 U WD III Lt tongue RT Partial late
71 subbammal 217 75 F low  +  -  -  +  - 3*3 N2a U WD IV a Rt cheek RT Partial late
72 arjunan 1506 55 M low  + 30p  -  -  - 3*2 N2a U WD IV a Lt tongue RT Partial late
73 chellammal 1507 30 F low  +  -  -  +  - 2*2 N1 I WD III Rt tongue RT Partial late
74 periyasamy 1538 65 M low  + 30p  -  -  - 3*2 N0 I MD II hard palateRT Complete early
75 ganapathi 2837 63 M low  + 20p  -  +  - 3*2 N2a U WD IV a Lt tongue RT Partial late
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76 utchimahali 3035 48 M low  + 20p  -  -  - 3*3 N1 U WD III Lt tongue RT Complete late
77 bala singh 3956 37 M low  +  -  -  +  - 4*3 N2c UP WD IV a Rt cheek RT Partial late
78 pappa 4202 58 F low  +  -  -  +  - 4*3 N2b UP MD IV a Rt cheek RT Partial late
79 kadarkarai 6748 65 M low  +  30p  -  -  - 3*2 N0 I MD II hard palateRT Complete early
80 manikandan 8825 42 M low  + 10p 1/d  -  - 3*2 N1 U MD III Rt tongue RT Partial late
81 ramaiah 9761 72 M low  + 30p  -  -  - 3*2 N0 I PD II hard palateRT Complete early
82 thangappan 10240 55 M low  - 15p 1/d  +  - 4*3 N2c P WD IV a Rt cheek S+RT®1R Partial late
83 chinnanadar 11043 65 M low  + 25p  -  -  - 4*3 N1 UP MD III Rt cheek RT Partial late
84 shanmugam 11068 50 M low  + 15p  -  +  - 3*2 N2a UP PD IV a Rt cheek RT Partial late
85 kumarasamy 13827 68 M low  + 30p  -  -  - 3*2 N2a UP PD IV a Rt cheek RT Partial late
86 sivanaiah 15071 62 M low  +  -  -  +  - 3*2 N1 U PD III Lt tongue RT Partial late
87 mariaselvam 18746 36 F low  +  -  -  +  - 2*1 N1 UP PD III Lt cheek RT Partial late
88 sudalaimuthu 22392 55 M low  + 25p 1/d  -  - 4*3 N1 U MD III Rt tongue RT Partial late
89 susaiammal 27392 72 F low  +  -  -  +  - 3*3 N2b UP PD IV a Lt cheek CT Partial late
90 lingam 36975 40 M low  + 20p 1/d  -  - 4*2 N1 U PD III Rt tongue CT Partial late
91 kalimuthu 39083 45 M low  + 20p  -  -  - 3*2 N2b U MD IV a Lt tongue CT Partial late
92 pathukannu 41721 57 F low  +  -  -  +  - 4*2 N2c UP MD IV a Lt cheek CT Partial late
93 subbaiah 43007 65 M low  + 30p  -  -  - 2*2 N1 U MD III Rt tongue CT Partial late
94 natarajan 44607 53 M low  + 15p  -  +  - 2*2 N0 I WD I hard palateCT Partial early
95 krishnasamy 44757 70 M low  + 30p  -  +  - 2*1.5 N0 U WD I Rt tongue S+RT Partial early
96 raj 46899 55 M low  + 20p  -  +  - 3*2 N0 I MD II hard palateCT Complete early
97 muthammal 47048 70 F low  -  -  -  +  - 2*2 N1 U PD III Lt tongue CT Partial late
98 madasamy 47078 70 M low  + 30p  -  -  - 3*2 N1 U PD III Rt tongue CT Partial late
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PROFORMA 
Case No:                                                                                 IP No: 
Name:                                                                                     DOA: 
Age:                                        Sex:                                         DOD: 
Address:                                                                Occupation: 
 
 
SE status:  
HISTORY 
Swelling 
Wound 
Difficulty in swallowing 
Excessive salivation 
Loss of tooth 
Spontaneous bleeding 
Difficulty in mouth opening 
Loss of weight and appetite 
Any other swelling  
H/o smoking- number of pack years  
H/o alcoholism- number of drinks per day 
H/o radiation exposure 
H/o STD and AIDS 
Pre-existing lesions 
H/o similar lesions in the past 
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Family history 
Co morbid illness 
Previous surgeries 
 
EXAMINATION 
 
General examination 
Build and nutrition/ BMI 
Vitals 
Pallor/ icterus/ cyanosis/ clubbing/ generalised lymphadenopathy 
Hydration status 
Examination of head and neck 
1. Upper jaw 
2. Lower jaw 
3. Temporomandibular joint 
4. Oral cavity- lips/tongue/palate/gums/floor of mouth/cheek 
5. Examination of salivary glands 
EXAMINATION OF REGIONAL LYMPH NODES: 
VASCULAR EXAMINATION: 
EXAMINATION OF FOR NERVE LESIONS: 
SYSTEMIC EXAMINATION: 
Cardiovascular system: 
Respiratory system: 
Abdominal examination: 
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INVESTIGATIONS: 
Urine Albumin:                                                Sugar: 
 
Micro: 
 
Blood-   Hb%                          TC:                           DC:                            ESR: 
Blood           Sugar:                       Urea:                          Creatinine: 
VDRL: 
HIV 
 
Culture and Sensitivity: 
 
Biopsy: 
X- rays 
 
Ultrasound abdomen 
 
CT scans 
 
MANAGEMENT 
 Surgical 
• Radiotherapy 
• Chemotherapy 
• Combined 
• Follow up 
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